Announcements Trials
Browse Landscape Eligibility

Clinical Trials

93 trials
RecentStart dateEnrollment
XELOX × Clear all

Phase

Phase 2 50Phase 3 23Phase 2/3 6Phase NA 4Phase 1/2 4Phase 4 2Phase 1 2

Status

Unknown 33Recruiting 21Completed 20Not yet recruiting 9Active not recruiting 6Withdrawn 2Terminated 2

Sponsor Class

OTHER 80INDUSTRY 7OTHER_GOV 6

Study Type

Interventional 91Observational 2

Sponsor

Cancer Type

Gastrointestinal 89Lymphoid 1

Conditions

Colorectal Neoplasms 26Stomach Neoplasms 24Rectal Neoplasms 22Colonic Neoplasms 12Neoplasms 3Neoplasm Metastasis 3Adenocarcinoma 3Gastrointestinal Neoplasms 2Waldenstrom Macroglobulinemia 1Recurrence 1Rcctal Cancer 1Peripheral Nervous System Diseases 1Metastatic HER2 Positive Gastroesophageal Junction Cancer 1Locally Advanced Rectal Cancer (LARC) 1Locally Advanced Rectal Cancer 1Locally Advanced Gastric Cancer 1Intestinal Neoplasms 1HER2-positive Locally Advanced Resectable Gastric Cancer 1HER2-positive Colorectal Cancer 1Gastrointestinal Diseases 1Gastric Cancer Stage 1Digestive System Diseases 1Colorectal Cancer Metastatic 1Colonic Diseases 1Carcinoma 1Adenocarcinoma of the Lower Rectum 1Adebrelimab (SHR-1316) 1

Interventions

Cyclophosphamide 2681Cisplatin 2665Carboplatin 2462Radiotherapy 2370Paclitaxel 2264Gemcitabine 2128pembrolizumab 1993Docetaxel 1883Bevacizumab 1821Fluorouracil 1548Capecitabine 1532Oxaliplatin 1440Dexamethasone 1330Nivolumab 1300Doxorubicin 1260Rituximab 1249Magnetic Resonance Spectroscopy 1150Etoposide 1126Irinotecan 1038Leucovorin 1020Drug Therapy 999Cytarabine 964Pemetrexed 891fludarabine 889Specimen Handling 822Vincristine 793Lenalidomide 791Cetuximab 785Prednisone 785Trastuzumab 785

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements
NCT05702229 2026-03-18

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

AstraZeneca

Phase 2 Recruiting
163 enrolled
Gastrointestinal

Stomach Neoplasms

NCT07468630 2026-03-12

TRIUNITE-08

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Phase 2 Recruiting
106 enrolled
Gastrointestinal

Colonic Neoplasms

NCT07453875 2026-03-06

TRIUNITE06

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Phase 1 Not yet recruiting
9 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT07448142 2026-03-04

Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer

Sun Yat-sen University

Phase 2 Recruiting
50 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT06346197 2026-03-02

CIME

Centre Leon Berard

Phase 3 Recruiting
132 enrolled
Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms

NCT04495088 2026-02-02

Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer

Universitätsmedizin Mannheim

Phase 3 Recruiting
550 enrolled
Gastrointestinal

Rectal Neoplasms

NCT07381777 2026-02-02

IMMUNOSTAR

Gruppo Oncologico Italiano di Ricerca Clinica

Phase 2 Not yet recruiting
270 enrolled
Gastrointestinal

Locally Advanced Rectal Cancer (LARC)

NCT07334431 2026-01-12

Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer

Henan Cancer Hospital

Phase 1/2 Recruiting
45 enrolled
Gastrointestinal

Stomach Neoplasms

NCT07229846 2026-01-08

A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation

Harbin Medical University

Phase 2 Not yet recruiting
30 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT07127497 2025-11-21

Clinical Study on the Safety and Relationship of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma

The First Affiliated Hospital of Anhui Medical University

Phase 2 Active not recruiting
50 enrolled
Gastrointestinal

Rectal Neoplasms

NCT03904043 2025-10-23

NOM-ERA

Washington University School of Medicine

Phase NA Active not recruiting
63 enrolled 9 charts

Adenocarcinoma of the Lower Rectum

NCT07007182 2025-09-05

Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer

Shandong Cancer Hospital and Institute

Phase 2 Not yet recruiting
54 enrolled
Gastrointestinal

Stomach Neoplasms

NCT07156682 2025-09-05

QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer

Qilu Hospital of Shandong University

Phase 2 Not yet recruiting
21 enrolled
Gastrointestinal

Colonic Neoplasms

NCT07132463 2025-08-20

Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study

Fudan University

Phase 3 Not yet recruiting
154 enrolled
Gastrointestinal

Rectal Neoplasms

NCT07108127 2025-08-06

NePHera

Peking Union Medical College Hospital

Phase 2 Recruiting
24 enrolled
Gastrointestinal

Rectal Neoplasms

NCT07068516 2025-07-16

Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer

Zhejiang Cancer Hospital

Phase 3 Not yet recruiting
470 enrolled
Gastrointestinal

Gastric Cancer Stage

NCT06848465 2025-05-11

LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Phase 1 Recruiting
9 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT01643070 2025-02-25

Preoperative CRT With or Without Induction Chemotherapy for Rectal Cancer With Liver Metastases

Asan Medical Center

Phase 2 Completed
38 enrolled 16 charts
Gastrointestinal

Rectal Neoplasms

NCT04380337 2025-02-25

Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer

Stanford University

Phase 2 Completed
38 enrolled 13 charts
Gastrointestinal

Rectal Neoplasms

NCT03662659 2025-02-05

An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers

Bristol-Myers Squibb

Phase 2 Completed
274 enrolled 19 charts
Gastrointestinal

Stomach Neoplasms

NCT06808412 2025-02-05

To Explore the Efficacy of Sintilimab Combined with Bevacizumab in Rectal Cancer

Xijing Hospital of Digestive Diseases

Phase 2 Recruiting
118 enrolled

Rcctal Cancer

NCT06475352 2025-01-27

FUDOSE

UNICANCER

Phase 2 Recruiting
400 enrolled
Gastrointestinal

Gastrointestinal Neoplasms, Neoplasm Metastasis, Neoplasms, Recurrence, Colorectal Neoplasms

NCT06128252 2025-01-07

Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer

Tang-Du Hospital

Phase NA Recruiting
96 enrolled
Gastrointestinal

Stomach Neoplasms

NCT03565029 2024-12-27

NO-CUT

Niguarda Hospital

Phase 2 Completed
180 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT01531595 2024-12-12

AXOAXI

Helsinki University Central Hospital

Phase 2 Active not recruiting
100 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT06242418 2024-12-12

REVISE

West China Hospital

Phase 2 Recruiting
60 enrolled
Gastrointestinal

Colonic Neoplasms

NCT06650332 2024-10-21

Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients

Zhejiang Cancer Hospital

Phase 1/2 Recruiting
90 enrolled
Gastrointestinal

Metastatic HER2 Positive Gastroesophageal Junction Cancer

NCT05086627 2024-08-22

Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer

Hebei Medical University Fourth Hospital

Phase 2 Completed
118 enrolled
Gastrointestinal

Locally Advanced Rectal Cancer

NCT06506292 2024-07-17

A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Recruiting
25 enrolled

Adebrelimab (SHR-1316)

NCT02355379 2024-07-08

ADAGE

Federation Francophone de Cancerologie Digestive

Phase 3 Recruiting
774 enrolled
Gastrointestinal

Colonic Neoplasms

NCT03714490 2024-05-29

SUNRISE

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting
200 enrolled
Gastrointestinal

Rectal Neoplasms

NCT06023758 2024-05-10

Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC

Peking University

Phase 2 Recruiting
18 enrolled
Gastrointestinal

HER2-positive Locally Advanced Resectable Gastric Cancer

NCT05228431 2024-04-22

Modified Sandwich Therapeutic Regimen for Locally Advanced Rectal Cancer

Sun Yat-sen University

Phase 2 Recruiting
121 enrolled
Gastrointestinal

Rectal Neoplasms

NCT04543695 2024-03-26

A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Active not recruiting
255 enrolled
Gastrointestinal

Rectal Neoplasms

NCT01910610 2024-03-12

STRATEGIC-1

GERCOR - Multidisciplinary Oncology Cooperative Group

Phase 3 Active not recruiting
464 enrolled
Gastrointestinal

Colorectal Cancer Metastatic

NCT06227325 2024-01-26

Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression

Henan Cancer Hospital

Phase 2 Unknown
27 enrolled
Gastrointestinal

Stomach Neoplasms

NCT05494060 2023-11-07

EXPLORING

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Recruiting
80 enrolled
Gastrointestinal

Carcinoma, Digestive System Diseases, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Stomach Neoplasms

NCT06115174 2023-11-02

CRC - PTX

Tanta University

Phase 4 Unknown
44 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT03840239 2023-10-25

TESS

Sun Yat-sen University

Phase 2 Active not recruiting
98 enrolled
Gastrointestinal

Rectal Neoplasms

NCT00958737 2023-09-29

IDEA

GERCOR - Multidisciplinary Oncology Cooperative Group

Phase 3 Unknown
2,000 enrolled
Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT05264896 2023-09-07

Perioperative FLOT vs Adjuvant XELOX for CA Stomach

Chinese University of Hong Kong

Phase 3 Recruiting
110 enrolled
Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT05985707 2023-08-21

KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma

Peking University Cancer Hospital & Institute

Phase 2 Not yet recruiting
80 enrolled
Gastrointestinal

HER2-positive Colorectal Cancer

NCT04659382 2023-08-18

SIRTCI

Federation Francophone de Cancerologie Digestive

Phase 2 Unknown
52 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT05969847 2023-08-01

TRACE-LE

Fujian Medical University Union Hospital

Phase 2 Not yet recruiting
72 enrolled
Gastrointestinal

Rectal Neoplasms

NCT05715632 2023-07-14

New Adjuvant Treatment of Locally Advanced Resectable Gastric Cancer With Carelizumab and XELOX

Tang-Du Hospital

Phase NA Unknown
46 enrolled
Gastrointestinal

Stomach Neoplasms

NCT05420584 2023-05-11

NECI

The Fourth Affiliated Hospital of Zhejiang University School of Medicine

Phase 2 Unknown
83 enrolled
Gastrointestinal

Rectal Neoplasms

NCT04522284 2023-03-29

PRECISE CURATE.AI Pilot Clinical Trial

National University Hospital, Singapore

Phase 1/2 Unknown
20 enrolled
Lymphoid

Waldenstrom Macroglobulinemia, Neoplasms

NCT04744649 2022-11-15

NICE

Nanfang Hospital, Southern Medical University

Phase 2 Unknown
110 enrolled
Gastrointestinal

Stomach Neoplasms

NCT05545436 2022-09-22

Carrelizumab (PD-1) Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer

Third Affiliated Hospital, Sun Yat-Sen University

Phase 2 Unknown
34 enrolled
Gastrointestinal

Locally Advanced Gastric Cancer

NCT05468138 2022-08-26

PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery

Fudan University

Phase 2 Unknown
141 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡